Who Paid My Doc
Daniel Weintraub
Psychiatry Philadelphia, PA Medical Doctor
NPI 1306865779 CMS profile 240336
3535 Market St., 3Rd Floor, Philadelphia, PA 19104
General payments
$646,888
Research payments
$600
Ownership & investment interest
$0
Through program year 2025, Daniel Weintraub of Philadelphia, PA is reported in the CMS Open Payments database as having received $646,888 across 130 general payments and $600 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 99th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $143,625 | 32 | |
| 2024 | General | $126,331 | 12 | |
| 2023 | General | $84,315 | 12 | |
| 2022 | General | $94,658 | 16 | |
| 2021 | General | $79,902 | 12 | |
| 2021 | Research | $600 | 1 | |
| 2020 | General | $60,985 | 21 | |
| 2019 | General | $57,072 | 25 |
Beside peers
- Daniel Weintraub
- Psychiatry median
- Middle half of Psychiatry
- National median
In program year 2025, general payments to Daniel Weintraub were reported at $143,625. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.
Show as a table
| Year | Daniel Weintraub | Psychiatry median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $57,072 | $184 | $59–$605 | $163 |
| 2020 | $60,985 | $119 | $36–$372 | $114 |
| 2021 | $79,902 | $143 | $43–$576 | $132 |
| 2022 | $94,658 | $153 | $50–$590 | $149 |
| 2023 | $84,315 | $170 | $56–$651 | $160 |
| 2024 | $126,331 | $179 | $57–$673 | $164 |
| 2025 | $143,625 | $180 | $58–$685 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 9 drugsPart D claims
266
Drug cost
$4,243
Branded share of claims
4.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Rivastigmine | Generic | 11 | $2,297 | |
| Paroxetine Hcl | Generic | 23 | $511 | |
| Escitalopram Oxalate | Generic | 38 | $486 | |
| Lorazepam | Generic | 47 | $295 | |
| Clonazepam | Generic | 77 | $238 | |
| Mirtazapine | Generic | 29 | $209 | |
| Venlafaxine Hcl Er Venlafaxine Hcl | Brand | 12 | $81 | |
| Trazodone Hcl | Generic | 14 | $65 | |
| Alprazolam | Generic | 15 | $61 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.
Payments and prescribing
2 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| Leqembi |
|
$122,936 | — | — |
| VRAYLAR |
|
$2,300 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
131 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Psychiatry in Pennsylvania
Related records
Psychiatry in Pennsylvania
Practitioners in the same specialty and state, ranked by reported value.
All Psychiatry
Everyone recorded under this specialty, nationwide.
Doctors in Pennsylvania
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.